Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSAID study

This article was originally published in The Tan Sheet

Executive Summary

Arthritic patients who took NSAIDs for more than three months had considerably more intestinal damage than patients taking acetaminophen or nothing for their pain, researcher David Graham tells attendees at Digestive Disease Week in Orlando, Fla. May 17-22. Investigators studied pictures taken with video capsule endoscopy and looked for "definite erosions as the critical variable to predict NSAID-induced damage." Seventy-one percent of high-dose ibuprofen, naproxen and indomethacin users had damage compared to 10% of non-users. "Severe injury" was seen in 25% of NSAID users compared to zero in the non-user group, researchers say. Study investigators hope their results "open the way to studies comparing NSAID[s], identifying methods to prevent this damage" and attempting to equate damage with symptoms...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095506

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel